Pharmacological modulation of endoglin expression in the liver in an animal model of nonalcoholic steatohepatitis

• Thesis title in Czech: Farmakologické ovlivnění exprese endoglinu v játrech na zvířecím modelu nealkoholické steatohepatitidy
• Thesis title in English: Pharmacological modulation of endoglin expression in the liver in an animal model of nonalcoholic steatohepatitis
• Academic year of topic announcement: 2022/2023
• Thesis type: diploma thesis
• Thesis language: angličtina
• Department: Department of Biological and Medical Sciences (16-16150)
• Supervisor: prof. PharmDr. Petr Nachtigal, Ph.D.
• Author: hidden - assigned by the advisor
• Date of registration: 26.09.2022
• Date of assignment: 22.11.2023
• Date and time of defence: 05.06.2024 08:00
• Date of electronic submission: 02.05.2024
• Date of proceeded defence: 05.06.2024
• Opponents: PharmDr. Jana Urbánková Rathouská, Ph.D.

Guidelines

Processing of literature research.
Work in the laboratory - mastering methodologies.
Writing up the thesis.

References

1. Vicen, M., Igreja Sa, I. C., Tripska, K., Vitverova, B., Najmanova, I., Eissazadeh, S., Micuda, S., and Nachtigal, P. (2020) Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell Mol Life Sci
2. Stols-Goncalves, D., Hovingh, G. K., Nieuwdorp, M., and Holleboom, A. G. (2019) NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends in endocrinology and metabolism: TEM30, 891-902
3. Janssen, A., Grobbee, D. E., and Dendale, P. (2020) Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol27, 1059-1063
4. Bot, P. T., Hoefer, I. E., Sluijter, J. P., van Vliet, P., Smits, A. M., Lebrin, F., Moll, F., de Vries, J. P., Doevendans, P., Piek, J. J., Pasterkamp, G., and Goumans, M. J. (2009) Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke40, 439-447
5. St-Jacques, S., Cymerman, U., Pece, N., and Letarte, M. (1994) Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology134, 2645-2657
6. Meurer, S., Wimmer, A. E., Leur, E. V., and Weiskirchen, R. (2019) Endoglin Trafficking/Exosomal Targeting in Liver Cells Depends on N-Glycosylation. Cells8
7. Lastres, P., Bellon, T., Cabanas, C., Sanchez-Madrid, F., Acevedo, A., Gougos, A., Letarte, M., and Bernabeu, C. (1992) Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol22, 393-397
8. Santibanez, J. F., Quintanilla, M., and Bernabeu, C. (2011) TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond)121, 233-251
9. Munoz-Felix, J. M., Gonzalez-Nunez, M., and Lopez-Novoa, J. M. (2013) ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe? Cytokine Growth Factor Rev24, 523-537
10. Nachtigal, P., Zemankova Vecerova, L., Rathouska, J., and Strasky, Z. (2012) The role of endoglin in atherosclerosis. Atherosclerosis224, 4-11
11. Medvedev, N. V., and Gorshukova, N. K. (2013) [Pathogenetic significance of interstitial fibrosis in development myocardial dysfunction and chronic heart failure in elderly patients with arterial hypertension]. Advances in gerontology = Uspekhi gerontologii / Rossiiskaia akademiia nauk, Gerontologicheskoe obshchestvo26, 130-136
12. Csanyi, G., Gajda, M., Franczyk-Zarow, M., Kostogrys, R., Gwozdz, P., Mateuszuk, L., Sternak, M., Wojcik, L., Zalewska, T., Walski, M., and Chlopicki, S. (2012) Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins & other lipid mediators98, 107-115
13. Vicen, M., Vitverova, B., Havelek, R., Blazickova, K., Machacek, M., Rathouska, J., Najmanova, I., Dolezelova, E., Prasnicka, A., Sternak, M., Bernabeu, C., and Nachtigal, P. (2019) Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J33, 6099-6114
14. Rossi, E., Sanz-Rodriguez, F., Eleno, N., Duwell, A., Blanco, F. J., Langa, C., Botella, L. M., Cabanas, C., Lopez-Novoa, J. M., and Bernabeu, C. (2013) Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood121, 403-415
15. Rinella, M. E. (2015) Nonalcoholic fatty liver disease: a systematic review. Jama313, 2263-2273
16. Younossi, Z. M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., and Henry, L. (2020) Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clinical Gastroenterology and Hepatology
17. Meurer, S. K., Alsamman, M., Scholten, D., and Weiskirchen, R. (2014) Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem5, 180-203
18. Meurer, S. K., Tihaa, L., Borkham-Kamphorst, E., and Weiskirchen, R. (2011) Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal23, 683-699
19. Finnson, K. W., and Philip, A. (2012) Endoglin in liver fibrosis. J Cell Commun Signal6, 1-4
20. Alsamman, M., Sterzer, V., Meurer, S. K., Sahin, H., Schaeper, U., Kuscuoglu, D., Strnad, P., Weiskirchen, R., Trautwein, C., and Scholten, D. (2018) Endoglin in human liver disease and murine models of liver fibrosis-A protective factor against liver fibrosis. Liver Int38, 858-867
21. Igreja Sa, I. C., Tripska, K., Hroch, M., Hyspler, R., Ticha, A., Lastuvkova, H., Schreiberova, J., Dolezelova, E., Eissazadeh, S., Vitverova, B., Najmanova, I., Vasinova, M., Pericacho, M., Micuda, S., and Nachtigal, P. (2020) Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver. Int J Mol Sci21
22. Rathouska, J., Jezkova, K., Nemeckova, I., and Nachtigal, P. (2015) Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis243, 383-388
23. Gallardo-Vara, E., Gamella-Pozuelo, L., Perez-Roque, L., Bartha, J. L., Garcia-Palmero, I., Casal, J. I., Lopez-Novoa, J. M., Pericacho, M., and Bernabeu, C. (2020) Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4. Cells9
24. Vitverova, B., Blazickova, K., Najmanova, I., Vicen, M., Hyspler, R., Dolezelova, E., Nemeckova, I., Tebbens, J. D., Bernabeu, C., Pericacho, M., and Nachtigal, P. (2018) Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis271, 15-25
25. Seon, B. K., Haba, A., Matsuno, F., Takahashi, N., Tsujie, M., She, X., Harada, N., Uneda, S., Tsujie, T., Toi, H., Tsai, H., and Haruta, Y. (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv8, 135-143
26. Li, Q., Lin, F., Ke, D., Cheng, Q., Gui, Y., Zhou, Y., Wu, Y., Wang, Y., and Zhu, P. (2020) Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition. J Atheroscler Thromb27, 331-341
27. Kumar, S., Pan, C. C., Bloodworth, J. C., Nixon, A. B., Theuer, C., Hoyt, D. G., and Lee, N. Y. (2014) Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling. Oncogene33, 3970-3979
28. Santibanez, J. F., Letamendia, A., Perez-Barriocanal, F., Silvestri, C., Saura, M., Vary, C. P., Lopez-Novoa, J. M., Attisano, L., and Bernabeu, C. (2007) Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol210, 456-468
29. Castonguay, R., Werner, E. D., Matthews, R. G., Presman, E., Mulivor, A. W., Solban, N., Sako, D., Pearsall, R. S., Underwood, K. W., Seehra, J., Kumar, R., and Grinberg, A. V. (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem286, 30034-30046
30. Schierwagen, R., Maybuchen, L., Zimmer, S., Hittatiya, K., Back, C., Klein, S., Uschner, F. E., Reul, W., Boor, P., Nickenig, G., Strassburg, C. P., Trautwein, C., Plat, J., Lutjohann, D., Sauerbruch, T., Tacke, F., and Trebicka, J. (2015) Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Scientific reports5, 12931
31. Paauwe, M., Heijkants, R. C., Oudt, C. H., van Pelt, G. W., Cui, C., Theuer, C. P., Hardwick, J. C., Sier, C. F., and Hawinkels, L. J. (2016) Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene35, 4069-4079
32. Dai, C., Xiao, X., Li, D., Tun, S., Wang, Y., Velkov, T., and Tang, S. (2018) Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death Dis9, 1164
33. Nachtigal, P., Pospisilova, N., Jamborova, G., Pospechova, K., Solichova, D., Andrys, C., Zdansky, P., Micuda, S., and Semecky, V. (2008) Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci82, 708-717
34. Dai, C., Xiao, X., Li, D., Tun, S., Wang, Y., Velkov, T., and Tang, S. (2018) Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. Cell Death & Disease9, 1-13